INS and Renal insufficiency: The AWARD studies 7–9 are still ongoing, with results expected soon (AWARD 7: a study in patients with renal insufficiency dulaglutide vs. insulin glargine with insulin lispro in both study arms [ClinicalTrials.gov identifier: NCT01621178], AWARD 8: dulaglutide vs. placebo as add on to sulfonylurea [ClinicalTrials.gov identifier: NCT01769378], AWARD 9: dulaglutide vs. placebo as add on to metformin and insulin glargine [ClinicalTrials.gov identifier: NCT02152371]).